A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout

Inclusion Criteria: 1. Male or female age 20 to 65 years, inclusive. 2. Meets ≥6 of the 12 American College of Rheumatology preliminary criteria (1977) for the classification of acute arthritis of primary gout (Appendix 2), OR have proven tophus or documented monosodium urate (MSU) crystals in the joint fluid. 3. Serum uric acid ≥7.5 mg/dL and ≤10 mg/dL at screening with ≥1 gouty arthritis flare within one year prior to screening, OR serum uric acid ≥9 mg/dL and ≤10 mg/dL at screening with or without prior gout flares. Exclusion Criteria: 1. Use of allopurinol, febuxostat, benzbromarone, probenecid, or sulfinpyrazone within 2 weeks prior to screening. 2. Occurrence of a gouty arthritis flare within 1 week prior to screening or during the screening period through baseline. 3. Use of colchicine within 1 week prior to screening. 4. Use of Glucocorticoids, NSAIDs or COX-2 inhibitors within 1 week prior to screening. 5. Allergy, contraindication, or intolerance to febuxostat. 6. Severe renal impairment. 7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentration \>2 times the upper limit of laboratory normal range (\>2x ULN) at screening.